Clinical Trials in San Francisco

Showing 9661-9680 of 12,991 trials

Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors

NCT00878904

RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panobinostat together with epirubicin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with epirubicin in treating patients with metastatic malignant solid tumors.

Unspecified Adult Solid Tumor, Protocol Specific

University of California, San Francisco40 participantsStarted Sep 2009

San Francisco, California, United States

COMPLETEDPhase 2< 1 mile

Clinical Trial Nuedexta in Subjects With ALS

NCT01806857

The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS).

Amyotrophic Lateral Sclerosis (ALS)

Center for Neurologic Study, La Jolla, California,90 participantsStarted Apr 2013

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Grand Rapids, Michigan, United States +4 more locations

COMPLETEDPhase 3< 1 mile

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

NCT00632736

To evaluate the safety profile of ropinirole XL during long-term treatment in subjects with early and advanced Parkinson's disease

Parkinson DiseaseParkinson's Disease

GlaxoSmithKline419 participantsStarted Feb 2004

Birmingham, Alabama, United States • Fountain Valley, California, United States • San Francisco, California, United States +72 more locations

Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors

Clinical Trial Nuedexta in Subjects With ALS

An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease

Find Trials by Condition in San Francisco

Natalizumab Re-Initiation of Dosing

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes

Post-Approval Study to Investigate the Long Term (8 Year) Survivorship of STAR Ankle Among Continued Access Study Patients

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Observational Plan to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device

STIP: Statin Trial for Influenza Patients

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study In People With Type 2 Diabetes

Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States

Improving Care and Reducing Cost Study

Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples

Short Term Pancreatic Stenting Registry

Caffeine as a Therapy for Parkinson's Disease